Bone Metastasis Treatment Industry Detailed Analysis, Growth Factors, Top Key Companies, Trends and Developments, 2018-2023
Bone Metastasis
Treatment Industry Research Report, by Type (Osteolytic, Osteoblastic, Mixed),
Diagnosis (Biopsy, Blood Test, Imaging), Treatment (Medical Therapies, Surgery,
Medication), End User (Hospital, Diagnostic Centers) - Global Forecast Till
2023
Market Highlights
The global Bone Metastasis Treatment Industry is expected
to grow at an approximate CAGR of 8.4% during the forecast period The
increasing prevalence of breast cancer, growing geriatric population, rising
healthcare expenditures, and increasing R&D expenses by the key players are
estimated to drive the market growth during the forecast period. However,
factors such as lack of healthcare services in low-income countries, the high
cost of treatment, and related side effects are estimated to restrain the
market growth during the forecast period.
Segmentation
The global Bone Metastasis Treatment
Industry is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is
segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed
bone metastasis, and others. On the basis of diagnosis, the market is
categorized into biopsy, blood test, imaging, and others. The imaging segment
is sub-segmented into X-ray, bone scintigraphy, computerized tomography,
magnetic resonance imaging, positron emission tomography, and others. On the
basis of treatment, the market is segmented into medical therapies, surgery,
medication, and others. The medical therapies segment is sub-segmented into
chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others.
The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and
others. The medication segment is sub-segmented into pain medications, bone
building medications, and others. On the basis of end-user, the market is
segmented into hospitals and clinics, diagnostic centers, pharmacies, and
ambulatory surgical centers.
Regional Analysis
America dominates the global Bone
Metastasis Treatment Industry owing to the presence of a well-developed
healthcare sector, increasing prevalence of breast cancer, and rising
healthcare sector within the region. Europe stands second in the market and is
followed by Asia Pacific owing to the availability of funds for research and a
huge patient population. Europe is segmented into Western Europe and Eastern
Europe. Western Europe leads the regional market due to the presence of
developed economies such as Italy, Germany, France, and others within the
region. Asia Pacific is projected to be the fastest growing region in the global
Bone Metastasis Treatment Industry. The presence of a developing healthcare
sector and increasing prevalence of cancer are expected to be the major drivers
for the market growth during the forecast period. The Middle East and Africa
holds the least share in the market. This can be attributed to the presence of
poor economies, stringent government policies, and lack of healthcare services,
especially within the African region.
Key Players
The key players in the global Bone
Metastasis Treatment Industry are F. Hoffmann-La Roche Ltd (Switzerland)
Bayer AG (Germany), Merck & Co., Inc.
(U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence Inc.
(England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC (U.S.),
Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others.
Comments
Post a Comment